HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering was supported by key stakeholders including ClearCardio, company leadership, and institutional investors. The funds will be used to accelerate the commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection technologies, expand AI capabilities, and for general corporate purposes.
HeartBeam is a medical technology company focused on transforming the detection and monitoring of critical cardiac conditions. The company is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. For more details, the full press release is available at https://ibn.fm/9iNYY and the latest news and updates can be found in the company's newsroom at https://ibn.fm/BEAT.
This capital raise is a significant step for HeartBeam as it moves toward broader commercialization of its cardiac monitoring solutions. The funds will support the rollout of its innovative ECG technology, which has the potential to improve access to cardiac care by enabling remote monitoring and early detection of heart conditions. The company's focus on AI capabilities also suggests future enhancements in diagnostic accuracy and predictive analytics.
HeartBeam's technology addresses a critical need in cardiac care: the ability to obtain high-quality ECG data outside of clinical settings. By synthesizing a 12-lead ECG from a compact, cable-free device, the company aims to provide physicians with comprehensive cardiac information that was previously only available in hospitals. This could lead to faster diagnosis and treatment for patients experiencing cardiac events, potentially reducing mortality and healthcare costs.
The involvement of ClearCardio and institutional investors indicates confidence in HeartBeam's technology and market potential. With FDA clearances already obtained for arrhythmia assessment and 12-lead ECG synthesis, the company is positioned to compete in the growing remote cardiac monitoring market. The extended-wear patch and heart attack detection technologies under development could further expand its product portfolio and address additional unmet clinical needs.
HeartBeam's success will depend on its ability to execute its commercialization strategy and secure reimbursement from payers. The $10 million offering provides necessary capital to support sales, marketing, and further R&D efforts. As the company advances its AI capabilities, it may also enhance the value proposition of its platform by offering predictive insights and decision support tools for clinicians.
For more information about HeartBeam and its cleared indications for use, visit https://www.heartbeam.com/indications.
